Replimune (REPL) Net Income towards Common Stockholders Growth (3y) (2020 - 2025)
Replimune (REPL) Net Income towards Common Stockholders Growth (3y) (2020 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
84.25% |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
-10.84% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
26.38% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-46.86% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
34.98% |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
13.80% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Replimune |
780.01 Mn |
510.88 Mn |
- |
-21.35% |
| Date | Value |
|---|
| Dec 31, 2025 |
-21.35% |
| Sep 30, 2025 |
-24.46% |
| Jun 30, 2025 |
-27.07% |
| Mar 31, 2025 |
-32.74% |
| Dec 31, 2024 |
-30.76% |
| Sep 30, 2024 |
-21.81% |
| Jun 30, 2024 |
-25.34% |
| Mar 31, 2024 |
-36.83% |
| Dec 31, 2023 |
-32.89% |
| Sep 30, 2023 |
-44.03% |
| Jun 30, 2023 |
-41.49% |
| Mar 31, 2023 |
-46.10% |
| Dec 31, 2022 |
-34.84% |
| Sep 30, 2022 |
-56.99% |
| Jun 30, 2022 |
-64.41% |
| Mar 31, 2022 |
-68.24% |
| Dec 31, 2021 |
-56.97% |
| Sep 30, 2021 |
-65.63% |
| Jun 30, 2021 |
-39.58% |
| Mar 31, 2021 |
-46.43% |
